Beat Schaer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Beat Schaer has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Christian Sticherling
Department of Cardiology, University Hospital Basel, University Basel , Basel
21 shared publications Stefan Osswald
Department of Cardiology, University Hospital, Basel, Switzerland
16 shared publications- Michael Kühne
Department of Cardiology, University Hospital Basel , Petersgraben 4, Basel 4031
12 shared publications Dominic A. Theuns
Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
4 shared publications- Luc Jordaens
Kliniek Sint Jan, Brussels, Belgium.
4 shared publications S. Osswald
Department of Cardiology, University of Basel Hospital, Basel, Switzerland
4 shared publications
Latest Publications
- Open Access
- 22 January 2020
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 26 (6) , 711-716
Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study
Background: Guidelines of heart failure therapy include cardiac resynchronization as standard of care in patients with severely depressed left ventricular function and wide QRS complex. It has been shown that patients benefit regarding mortality and morbidity. However, early mortality precludes long-term benefits from the device. The aim of the study was to identify predictors for early occurrence of both death and first-ever implantable cardioverter-defibrillator (ICD) therapy using a large combined database of patients with cardiac resynchronization therapy with defibrillator (CRT-D). Methods: From two registries (tertiary care centres) 904 patients were identified, no single patient was excluded. Early death was defined as death occurring within the 3 years after implantation whereas early ICD therapy as such occurring within the first year. 33 baseline parameters were compared using uni- and multivariate analysis with the Cox model and binary logistic regression. Results: The population was predominantly male (77%), with mean age of 63 ± 11 years and primary prevention indication in 80%. Mean follow-up was 55 ± 38 months. 256 (28%) patients had ICD therapies whereof the first-ever event occurred early in 52%. 270 (30%) patients died after 41 ± 31 months, mostly from advancing heart failure (41%), 141 (52%) patients of them early. Independent predictors for early ICD therapy were secondary prevention and renal failure. Independent predictors for early mortality were a history of percutaneous coronary intervention and of peripheral vascular disease. Conclusions: Predictors for early mortality after CRT-D implantation were a history of percutaneous coronary intervention and peripheral vascular disease, present in only a minority of patients, thus limiting their use in clinical practice. Background: Guidelines of heart failure therapy include cardiac resynchronization as standard of care in patients with severely depressed left ventricular function and wide QRS complex. It has been shown that patients benefit regarding mortality and morbidity. However, early mortality precludes long-term benefits from the device. The aim of the study was to identify predictors for early occurrence of both death and first-ever implantable cardioverter-defibrillator (ICD) therapy using a large combined database of patients with cardiac resynchronization therapy with defibrillator (CRT-D). Methods: From two registries (tertiary care centres) 904 patients were identified, no single patient was excluded. Early death was defined as death occurring within the 3 years after implantation whereas early ICD therapy as such occurring within the first year. 33 baseline parameters were compared using uni- and multivariate analysis with the Cox model and binary logistic regression. Results: The population was predominantly male (77%), with mean age of 63 ± 11 years and primary prevention indication in 80%. Mean follow-up was 55 ± 38 months. 256 (28%) patients had ICD therapies whereof the first-ever event occurred early in 52%. 270 (30%) patients died after 41 ± 31 months, mostly from advancing heart failure (41%), 141 (52%) patients of them early. Independent predictors for early ICD therapy were secondary prevention and renal failure. Independent predictors for early mortality were a history of percutaneous coronary intervention and of peripheral vascular disease. Conclusions: Predictors for early mortality after CRT-D implantation were a history of percutaneous coronary intervention and peripheral vascular disease, present in only a minority of patients, thus limiting their use in clinical practice.
- 22 January 2020
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 26 (6) , 711-716
Open AccessPredictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study
Background: Guidelines of heart failure therapy include cardiac resynchronization as standard of care in patients with severely depressed left ventricular function and wide QRS complex. It has been shown that patients benefit regarding mortality and morbidity. However, early mortality precludes long-term benefits from the device. The aim of the study was to identify predictors for early occurrence of both death and first-ever implantable cardioverter-defibrillator (ICD) therapy using a large combined database of patients with cardiac resynchronization therapy with defibrillator (CRT-D). Methods: From two registries (tertiary care centres) 904 patients were identified, no single patient was excluded. Early death was defined as death occurring within the 3 years after implantation whereas early ICD therapy as such occurring within the first year. 33 baseline parameters were compared using uni- and multivariate analysis with the Cox model and binary logistic regression. Results: The population was predominantly male (77%), with mean age of 63 ± 11 years and primary prevention indication in 80%. Mean follow-up was 55 ± 38 months. 256 (28%) patients had ICD therapies whereof the first-ever event occurred early in 52%. 270 (30%) patients died after 41 ± 31 months, mostly from advancing heart failure (41%), 141 (52%) patients of them early. Independent predictors for early ICD therapy were secondary prevention and renal failure. Independent predictors for early mortality were a history of percutaneous coronary intervention and of peripheral vascular disease. Conclusions: Predictors for early mortality after CRT-D implantation were a history of percutaneous coronary intervention and peripheral vascular disease, present in only a minority of patients, thus limiting their use in clinical practice. Background: Guidelines of heart failure therapy include cardiac resynchronization as standard of care in patients with severely depressed left ventricular function and wide QRS complex. It has been shown that patients benefit regarding mortality and morbidity. However, early mortality precludes long-term benefits from the device. The aim of the study was to identify predictors for early occurrence of both death and first-ever implantable cardioverter-defibrillator (ICD) therapy using a large combined database of patients with cardiac resynchronization therapy with defibrillator (CRT-D). Methods: From two registries (tertiary care centres) 904 patients were identified, no single patient was excluded. Early death was defined as death occurring within the 3 years after implantation whereas early ICD therapy as such occurring within the first year. 33 baseline parameters were compared using uni- and multivariate analysis with the Cox model and binary logistic regression. Results: The population was predominantly male (77%), with mean age of 63 ± 11 years and primary prevention indication in 80%. Mean follow-up was 55 ± 38 months. 256 (28%) patients had ICD therapies whereof the first-ever event occurred early in 52%. 270 (30%) patients died after 41 ± 31 months, mostly from advancing heart failure (41%), 141 (52%) patients of them early. Independent predictors for early ICD therapy were secondary prevention and renal failure. Independent predictors for early mortality were a history of percutaneous coronary intervention and of peripheral vascular disease. Conclusions: Predictors for early mortality after CRT-D implantation were a history of percutaneous coronary intervention and peripheral vascular disease, present in only a minority of patients, thus limiting their use in clinical practice.
- Open Access
- 25 November 2015
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 18 (5) , 710-717
Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time
Longevity of implantable cardioverter defibrillators (ICDs) is crucial for patients and healthcare systems as replacements impact on infection rates and cost-effectiveness. Aim was to determine longevity using very large databases of two teaching hospitals with a high number of replacements and a rather homogeneous distribution among manufacturers. The study population consists of all patients in whom an ICD was inserted in. All ICD manufacturers operating in Switzerland and the Netherlands and all implanted ICDs were included. Implantable cardioverter defibrillator replacements due to normal battery depletion were considered events, and other replacements were censored. Longevity was assessed depending on manufacturers, pacing mode, implant before/after 2006, and all parameters combined. We analysed data from 3436 patients in whom 4881 ICDs [44.2% VVI-ICDs, 27.4% DDD-ICDs, 26.3% cardiac resynchronization therapy (CRT)-ICDs, 2.0% subcutaneous ICDs] were implanted. The four major manufacturers had implant shares between 18.4 and 31.5%. Replacement due to battery depletion (27.4%) was performed for 1339 ICDs. Patient survival at 5 years was 80.1%. Longevity at 5 years improved in contemporary compared with elderly ICDs [63.9–80.6% across all ICDs, of 73.7–92.1% in VVIs, 58.2–76.1% in DDDs, and of 47.1–66.3% in CRT defibrillators, all P value < 0.05]. Remarkable differences were seen among manufacturers, and those with better performance in elderly ICDs were not those with better performance in contemporary ones. Implantable cardioverter defibrillator longevity increased in contemporary models independent of manufacturer and pacing mode. Still, significant differences exist among manufacturers. These results might impact on device selection.
- 25 November 2015
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 18 (5) , 710-717
Open AccessLongevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time
Longevity of implantable cardioverter defibrillators (ICDs) is crucial for patients and healthcare systems as replacements impact on infection rates and cost-effectiveness. Aim was to determine longevity using very large databases of two teaching hospitals with a high number of replacements and a rather homogeneous distribution among manufacturers. The study population consists of all patients in whom an ICD was inserted in. All ICD manufacturers operating in Switzerland and the Netherlands and all implanted ICDs were included. Implantable cardioverter defibrillator replacements due to normal battery depletion were considered events, and other replacements were censored. Longevity was assessed depending on manufacturers, pacing mode, implant before/after 2006, and all parameters combined. We analysed data from 3436 patients in whom 4881 ICDs [44.2% VVI-ICDs, 27.4% DDD-ICDs, 26.3% cardiac resynchronization therapy (CRT)-ICDs, 2.0% subcutaneous ICDs] were implanted. The four major manufacturers had implant shares between 18.4 and 31.5%. Replacement due to battery depletion (27.4%) was performed for 1339 ICDs. Patient survival at 5 years was 80.1%. Longevity at 5 years improved in contemporary compared with elderly ICDs [63.9–80.6% across all ICDs, of 73.7–92.1% in VVIs, 58.2–76.1% in DDDs, and of 47.1–66.3% in CRT defibrillators, all P value < 0.05]. Remarkable differences were seen among manufacturers, and those with better performance in elderly ICDs were not those with better performance in contemporary ones. Implantable cardioverter defibrillator longevity increased in contemporary models independent of manufacturer and pacing mode. Still, significant differences exist among manufacturers. These results might impact on device selection.
- 10 June 2015
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 18 (2) , 227-231
Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication
Aims Incidence of implantable cardioverter-defibrillator (ICD) therapy in secondary prevention has been assessed in randomized trials and registries. However, results are considerably limited by short follow-up and hazy definition of treated arrhythmias. This study aimed to determine appropriate ICD therapy and to define predictors based on registry patients followed for up to 20 years. Methods and results All patients with a secondary prevention indication and ischaemic or dilated cardiomyopathy were identified. Arrhythmic endpoints were appropriate ICD therapies for any ventricular tachycardia (VT) >175 b.p.m. and appropriate ICD therapies in the ventricular fibrillation (VF) zone of >220 b.p.m. (potentially life-threatening). Predictors were determined by analysing 19 baseline characteristics. We included 357 patients, age 65 ± 11 years, predominantly male (89%) with ischaemic cardiomyopathy (83%). During follow-up of 82 ± 53 months, 156 (44%) patients died and 208 received any form of ICD therapies (59%), 71 of them (34%) in the VF zone. Forty-four patients (28%) died without experiencing any form of appropriate ICD therapy. Cumulative incidence of any form of ICD therapy at 10 years was 65%. Predictors for any form of ICD therapy were implantation for VT and age [VT: hazard ratio (HR) 1.45, 95% confidence interval (95% CI) 1.05–2.01, P = 0.03; age (per year): HR 1.02, 95% CI 1.01–1.04, P = 0.001]. For therapy in the VF zone, univariate analysis determined male gender (29 vs. 5%, P = 0.01) as predictor. Conclusion The rate of appropriate ICD therapies in secondary prevention is high. No useful predictors for them, especially not for life-threatening arrhythmias could be identified.
- 10 June 2015
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 18 (2) , 227-231
Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication
Aims Incidence of implantable cardioverter-defibrillator (ICD) therapy in secondary prevention has been assessed in randomized trials and registries. However, results are considerably limited by short follow-up and hazy definition of treated arrhythmias. This study aimed to determine appropriate ICD therapy and to define predictors based on registry patients followed for up to 20 years. Methods and results All patients with a secondary prevention indication and ischaemic or dilated cardiomyopathy were identified. Arrhythmic endpoints were appropriate ICD therapies for any ventricular tachycardia (VT) >175 b.p.m. and appropriate ICD therapies in the ventricular fibrillation (VF) zone of >220 b.p.m. (potentially life-threatening). Predictors were determined by analysing 19 baseline characteristics. We included 357 patients, age 65 ± 11 years, predominantly male (89%) with ischaemic cardiomyopathy (83%). During follow-up of 82 ± 53 months, 156 (44%) patients died and 208 received any form of ICD therapies (59%), 71 of them (34%) in the VF zone. Forty-four patients (28%) died without experiencing any form of appropriate ICD therapy. Cumulative incidence of any form of ICD therapy at 10 years was 65%. Predictors for any form of ICD therapy were implantation for VT and age [VT: hazard ratio (HR) 1.45, 95% confidence interval (95% CI) 1.05–2.01, P = 0.03; age (per year): HR 1.02, 95% CI 1.01–1.04, P = 0.001]. For therapy in the VF zone, univariate analysis determined male gender (29 vs. 5%, P = 0.01) as predictor. Conclusion The rate of appropriate ICD therapies in secondary prevention is high. No useful predictors for them, especially not for life-threatening arrhythmias could be identified.
- 20 January 2015
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 38 (3) , 306-310
Very Late Follow‐Up of a Passive Defibrillator Lead Under Recall: Do Failure Rates Increase during Long‐Term Observation
Background: The Medtronic Sprint Fidelis lead (SFL; Medtronic Inc., Minneapolis, MN, USA) has a significantly impaired long‐term survival, and active fixation leads fare worse than passive leads. The goal of this study was to present data of a series of passive SFL only with very long mean follow‐up of more than 6 years.Methods: Patients in whom a passive SFL was implanted in two large Swiss centers were followed. We excluded eight (5.5%) patients with a follow‐up of 1,500 or high‐voltage impedance >100 Ohm; >300 nonphysiological short interventricular‐intervals. Lenient = any of the above plus a linear increase in impedance >1,500 Ohm or a linear decrease in sensing to a level that treating cardiologists considered inappropriate.Results: We included 137 patients. Age was 60 ± 12 years. Mean and median follow‐up were 6.2 ± 2.1 and 6.8 (interquartile range 4.8–7.8) years. Applying the strict definition, 12 leads (8.8%) were replaced after 4.9 ± 2.4 years (range 1.2–8.1). Applying the lenient definition, 14 leads (10.2%) failed.Cumulative lead survival was 98.5% at 3, 96.9% at 4, 94.2% at 5, and 93.1% at 6 years. Leads “at risk” were: n = 122 (89%), 115 (84%), 101 (74%), and 88 (64%).Conclusions: In this population with passive SFLs, 5‐year lead survival is impaired with 94.2% based on 74% of leads “at risk” at this time point.
- 20 January 2015
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 38 (3) , 306-310
Very Late Follow‐Up of a Passive Defibrillator Lead Under Recall: Do Failure Rates Increase during Long‐Term Observation
Background: The Medtronic Sprint Fidelis lead (SFL; Medtronic Inc., Minneapolis, MN, USA) has a significantly impaired long‐term survival, and active fixation leads fare worse than passive leads. The goal of this study was to present data of a series of passive SFL only with very long mean follow‐up of more than 6 years.Methods: Patients in whom a passive SFL was implanted in two large Swiss centers were followed. We excluded eight (5.5%) patients with a follow‐up of 1,500 or high‐voltage impedance >100 Ohm; >300 nonphysiological short interventricular‐intervals. Lenient = any of the above plus a linear increase in impedance >1,500 Ohm or a linear decrease in sensing to a level that treating cardiologists considered inappropriate.Results: We included 137 patients. Age was 60 ± 12 years. Mean and median follow‐up were 6.2 ± 2.1 and 6.8 (interquartile range 4.8–7.8) years. Applying the strict definition, 12 leads (8.8%) were replaced after 4.9 ± 2.4 years (range 1.2–8.1). Applying the lenient definition, 14 leads (10.2%) failed.Cumulative lead survival was 98.5% at 3, 96.9% at 4, 94.2% at 5, and 93.1% at 6 years. Leads “at risk” were: n = 122 (89%), 115 (84%), 101 (74%), and 88 (64%).Conclusions: In this population with passive SFLs, 5‐year lead survival is impaired with 94.2% based on 74% of leads “at risk” at this time point.
- Open Access
- 20 October 2013
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 143 (4344) , w13863
Changes in renal function over time in patients with cardiac resynchronisation therapy
Cardiac resynchronisation therapy (CRT) with defibrillator back-up (CRT-D) is widely used in selected patients with moderate/severe heart failure. Renal failure is common in these patients. Data on the impact of CRT on renal function are controversial and limited by short follow-up. The aim of this study was to describe changes in glomerular filtration rate (GFR) from baseline compared with 1 and 2 years after CRT implantation. A total of 284 CRT-D patients with creatinine levels at baseline and after 1 year were identified in two prospective registries. In 149 patients, levels after 2 years were available. GFR in ml/min/1.73 m2 was estimated with the Modification Diet in Renal Disease equation and patients stratified into GFR stages 1 to 4. The population was predominantly male (75%), mean (± standard deviation) age was 61 ± 7 years and ejection fraction 24% ± 8 %. GFR was 63 ± 24 ml/min/1.73 m2 at implantation and 60 ± 24 ml/min/1.73 m2 after 1 year (p = 0.26). At the 2-year follow-up, GFR had decreased from 60 ± 21 to 56 ± 21 ml/min/1.73 m2 (p = 0.04). Mean GFR decreased in stages 1 and 2, remained stable in stage 3 and improved in stage 4 patients. After 2 years, GFR had decreased ≥10 ml/min/1.73 m2 in 42%, but improved in only 15% (p = 0.04). Overall, mean GFR in CRT-D patients decreases at 1 and 2 years after implantation, depending in part on the initial degree of renal function. However, the chance of further substantial deterioration (≥10 ml/min/1.73 m2) is considerable.
- 20 October 2013
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 143 (4344) , w13863
Open AccessChanges in renal function over time in patients with cardiac resynchronisation therapy
Cardiac resynchronisation therapy (CRT) with defibrillator back-up (CRT-D) is widely used in selected patients with moderate/severe heart failure. Renal failure is common in these patients. Data on the impact of CRT on renal function are controversial and limited by short follow-up. The aim of this study was to describe changes in glomerular filtration rate (GFR) from baseline compared with 1 and 2 years after CRT implantation. A total of 284 CRT-D patients with creatinine levels at baseline and after 1 year were identified in two prospective registries. In 149 patients, levels after 2 years were available. GFR in ml/min/1.73 m2 was estimated with the Modification Diet in Renal Disease equation and patients stratified into GFR stages 1 to 4. The population was predominantly male (75%), mean (± standard deviation) age was 61 ± 7 years and ejection fraction 24% ± 8 %. GFR was 63 ± 24 ml/min/1.73 m2 at implantation and 60 ± 24 ml/min/1.73 m2 after 1 year (p = 0.26). At the 2-year follow-up, GFR had decreased from 60 ± 21 to 56 ± 21 ml/min/1.73 m2 (p = 0.04). Mean GFR decreased in stages 1 and 2, remained stable in stage 3 and improved in stage 4 patients. After 2 years, GFR had decreased ≥10 ml/min/1.73 m2 in 42%, but improved in only 15% (p = 0.04). Overall, mean GFR in CRT-D patients decreases at 1 and 2 years after implantation, depending in part on the initial degree of renal function. However, the chance of further substantial deterioration (≥10 ml/min/1.73 m2) is considerable.
- 22 October 2012
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 24 (4) , 437-441
Role of Defibrillation Threshold Testing in the Contemporary Defibrillator Patient Population
Role of Defibrillation Threshold Testing. Introduction: Defibrillation threshold (DFT) testing has been performed to prove functionality of the implantable cardioverter defibrillator (ICD). Over the past years it has become increasingly controversial because of possible morbidity and mortality. The goal of this study was to determine unsuccessful shock testing and report strategies used to overcome these problems.Methods and Results: A total of 314 patients with a de novo implantation of an ICD and 127 patients receiving a generator exchange were identified retrospectively. All patients underwent defibrillation threshold testing after induction of VF using a low‐energy T‐wave shock during the intervention, 2 shock tests after de novo implantations, 1 after generator change. A safety margin of 10 J or more was requested. Seven (2.3%) patients in the de novo group and 2 patients (1.4%) in the generator exchange group could not be defibrillated using the standard approach. All of those patients had either chronic amiodarone therapy, secondary prevention or a cardiac resynchronization therapy device (CRT). In univariate analysis, amiodarone therapy, dilated cardiomyopathy, and lower ejection fraction were predictors of failure.Conclusion: Our study's results as well as a review of the current literature favor shock testing, especially in patients with specific risk factors as mentioned above. (J Cardiovasc Electrophysiol, Vol. 24, pp. 437‐441, April 2013)
- 22 October 2012
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 24 (4) , 437-441
Role of Defibrillation Threshold Testing in the Contemporary Defibrillator Patient Population
Role of Defibrillation Threshold Testing. Introduction: Defibrillation threshold (DFT) testing has been performed to prove functionality of the implantable cardioverter defibrillator (ICD). Over the past years it has become increasingly controversial because of possible morbidity and mortality. The goal of this study was to determine unsuccessful shock testing and report strategies used to overcome these problems.Methods and Results: A total of 314 patients with a de novo implantation of an ICD and 127 patients receiving a generator exchange were identified retrospectively. All patients underwent defibrillation threshold testing after induction of VF using a low‐energy T‐wave shock during the intervention, 2 shock tests after de novo implantations, 1 after generator change. A safety margin of 10 J or more was requested. Seven (2.3%) patients in the de novo group and 2 patients (1.4%) in the generator exchange group could not be defibrillated using the standard approach. All of those patients had either chronic amiodarone therapy, secondary prevention or a cardiac resynchronization therapy device (CRT). In univariate analysis, amiodarone therapy, dilated cardiomyopathy, and lower ejection fraction were predictors of failure.Conclusion: Our study's results as well as a review of the current literature favor shock testing, especially in patients with specific risk factors as mentioned above. (J Cardiovasc Electrophysiol, Vol. 24, pp. 437‐441, April 2013)
- 1 October 2012
- Vol. 103 (5) , 361-7
Adjustments of heart failure medication after implantation of a cardiac resynchronization therapy defibrillator.
"Optimal" medical therapy is mandatory before implantation of a cardiac resynchronization therapy (CRT) device, but "optimal" is not further specified. We determined the number of patients on a specific drug, the percentages of recommended target doses of the drugs the patients were on and their evolution over time. Drug therapy (ACE-inhibitors (ACE-I), AT-receptor antagonists (ARBs), betablockers) of 140 patients with a follow-up of at least one year was studied. Response to CRT was defined as reduction in NYHA class ≥1. Age was 66±9 years, follow-up 43±25 months during which 28 patients (20%) had died. At baseline, 81 % of patients were on a betablocker compared to 95% after 3 years (P-value 0.02). Percentages of target doses were 55±34% and increased to 68±41% after 3 years (P-value <0.02). Percentages were increased in responders (58±40% to 72±32%, P-value 0.01 after 3 years), but not in non-responders (57±31% to 56±38%). At baseline, 97% of patients were on ACE-Is/ARBs and 100% after 3 years. Mean percentages of target doses were 78±43% at implant and between 73±40% and 79±49% during follow-up. Percentages were stable both in responders (83% at implant, 78% after 3 years) and in non-responders (80%/87%, both P-value n.s.). Even though quantity and quality of drug therapy at baseline was on an acceptable (betablockers) or high (ACE-Is/ARBs) level, physicians must be very observant on therapy during long-term follow-up, especially on target doses of betablockers in non-responders.
- 1 October 2012
- Vol. 103 (5) , 361-7
Adjustments of heart failure medication after implantation of a cardiac resynchronization therapy defibrillator.
"Optimal" medical therapy is mandatory before implantation of a cardiac resynchronization therapy (CRT) device, but "optimal" is not further specified. We determined the number of patients on a specific drug, the percentages of recommended target doses of the drugs the patients were on and their evolution over time. Drug therapy (ACE-inhibitors (ACE-I), AT-receptor antagonists (ARBs), betablockers) of 140 patients with a follow-up of at least one year was studied. Response to CRT was defined as reduction in NYHA class ≥1. Age was 66±9 years, follow-up 43±25 months during which 28 patients (20%) had died. At baseline, 81 % of patients were on a betablocker compared to 95% after 3 years (P-value 0.02). Percentages of target doses were 55±34% and increased to 68±41% after 3 years (P-value <0.02). Percentages were increased in responders (58±40% to 72±32%, P-value 0.01 after 3 years), but not in non-responders (57±31% to 56±38%). At baseline, 97% of patients were on ACE-Is/ARBs and 100% after 3 years. Mean percentages of target doses were 78±43% at implant and between 73±40% and 79±49% during follow-up. Percentages were stable both in responders (83% at implant, 78% after 3 years) and in non-responders (80%/87%, both P-value n.s.). Even though quantity and quality of drug therapy at baseline was on an acceptable (betablockers) or high (ACE-Is/ARBs) level, physicians must be very observant on therapy during long-term follow-up, especially on target doses of betablockers in non-responders.
- Open Access
- 15 June 2012
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 14 (11) , 1620-1623
Long-term performance of the Medtronic Sprint Fidelis lead: a matter of lead type?
In 2007, the Medtronic™ Sprint Fidelis® lead was withdrawn from the market due to elevated failure rates. Since then, several studies were published with failure rates between 1.3 and 3.75%/year. However, they included a very high percentage of active fixation leads. Data in a population with passive leads are missing. All 166 patients who received a Fidelis lead between December 2004 and October 2007 in two teaching hospitals were identified. We excluded nine patients with incomplete data and 18 with active fixation leads. The study population thus consists of 139 patients with passive leads. Pacing and high-voltage impedance values were systematically collected at implant and in intervals of 6 months. Follow-up was 49 ± 15 months. All leads were 6948 models. During a follow-up of 41 ± 15 months, nine leads (6.5%) failed. Annual failure rate was 1.9%/year (95% CI 0.4–4.2), cumulative 5-year survival 95.8%. There were no differences between leads used in resynchronization and non-resynchronization devices (8.9 and 5.3%, P value 0.47). In a population with only passive leads, the Fidelis lead exhibited an impaired long-term survival, but performance was better than in previous studies in which >90% of leads were active models.
- 15 June 2012
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 14 (11) , 1620-1623
Open AccessLong-term performance of the Medtronic Sprint Fidelis lead: a matter of lead type?
In 2007, the Medtronic™ Sprint Fidelis® lead was withdrawn from the market due to elevated failure rates. Since then, several studies were published with failure rates between 1.3 and 3.75%/year. However, they included a very high percentage of active fixation leads. Data in a population with passive leads are missing. All 166 patients who received a Fidelis lead between December 2004 and October 2007 in two teaching hospitals were identified. We excluded nine patients with incomplete data and 18 with active fixation leads. The study population thus consists of 139 patients with passive leads. Pacing and high-voltage impedance values were systematically collected at implant and in intervals of 6 months. Follow-up was 49 ± 15 months. All leads were 6948 models. During a follow-up of 41 ± 15 months, nine leads (6.5%) failed. Annual failure rate was 1.9%/year (95% CI 0.4–4.2), cumulative 5-year survival 95.8%. There were no differences between leads used in resynchronization and non-resynchronization devices (8.9 and 5.3%, P value 0.47). In a population with only passive leads, the Fidelis lead exhibited an impaired long-term survival, but performance was better than in previous studies in which >90% of leads were active models.
- 30 November 2011
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 35 (9) , e280-e283
Remotely Monitored Death of a Patient with Implanted ICD
Remote monitoring is useful for management of implantable cardioverter defibrillator (ICD) patients regarding detection of arrhythmias and probable device or lead failure. We report the case of a patient who died suddenly while being on remote monitoring. The ICD was not retrieved postmortem. Even though clinical circumstances were suspicious of an arrhythmic death, this was excluded due to a distinctive manufacturer feature of the system.
- 30 November 2011
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 35 (9) , e280-e283
Remotely Monitored Death of a Patient with Implanted ICD
Remote monitoring is useful for management of implantable cardioverter defibrillator (ICD) patients regarding detection of arrhythmias and probable device or lead failure. We report the case of a patient who died suddenly while being on remote monitoring. The ICD was not retrieved postmortem. Even though clinical circumstances were suspicious of an arrhythmic death, this was excluded due to a distinctive manufacturer feature of the system.
- Open Access
- 28 June 2011
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 13 (11) , 1562-1567
Impact of left ventricular ejection fraction on occurrence of ventricular events in defibrillator patients with coronary artery disease
Primary preventive implantable cardioverter defibrillator (ICD) therapy is indicated in patients with coronary artery disease (CAD) and left ventricular ejection fraction (LVEF) of ≤ 35%, but some patients in the major trials had LVEF in the range of 30-35%. We hypothesized that these patients constitute a lower-risk population and might derive less benefit from ICD therapy.
- 28 June 2011
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 13 (11) , 1562-1567
Open AccessImpact of left ventricular ejection fraction on occurrence of ventricular events in defibrillator patients with coronary artery disease
Primary preventive implantable cardioverter defibrillator (ICD) therapy is indicated in patients with coronary artery disease (CAD) and left ventricular ejection fraction (LVEF) of ≤ 35%, but some patients in the major trials had LVEF in the range of 30-35%. We hypothesized that these patients constitute a lower-risk population and might derive less benefit from ICD therapy.